Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to learn about the effect of olive leaf tea (OLT) in patients with small intestinal bacterial overgrowth aging from 18 to 60 years old. This study aims to answer the following questions: - Will OLT consumption help decrease severity of gastrointestinal signs and symptoms - Will OLT help normalize the intestinal methane and hydrogen gases levels measured by glucose breath test - Does olive leaf tea have an effect on body composition parameters including weight, muscle mass and fat mass Participants with complain of gastrointestinal symptoms like abdominal gas, constipation, diarrhea etc. will undergo glucose breath test(GBT). Participants with diagnosed SIBO by GBT will randomly assigned to two groups. Group A will take the olive leaf tea(1.8g leave powder /tea bag) twice/day after meals for the duration of 2 months. Group B (control group) will not take olive leaf tea. For both groups Symptomatic questionnaire, Glucose breath test, Body composition by InBody analyzer 270 and 24-hour dietary recall will be taken. Researcher will compare readings of group A and Group B taken at Baseline and after 2 months of intervention to assess the effect of Olive leaf tea


Clinical Trial Description

Small intestinal bacterial overgrowth (SIBO), characterized by an abnormal increase in the population of overall or harmful bacteria species in the small intestine, resulting in malabsorption, malnutrition, alter body composition and can lead to further complications if not addressed timely. Herbal therapy is considered quite effective in treating SIBO. No literal data is available concerning therapeutic effect of olive leaf tea on SIBO patients. Olive leaves consist of high concentration of phenolic compounds and essential fatty acids that assist in restoring altered gut microbiota and in weight management, also possess significant antimicrobial effect against opportunistic intestinal bacteria. Objective of this study is to evaluate the antimicrobial potential of olive leaf infusion on intestinal microbiota analyzed by hydrogen and methane breath test and its effect on body composition parameters in SIBO individuals. This study will also observe the effect of OLT on gastrointestinal signs and symptoms. This study comprises of 3 phases: Phase 1: Olive leaf tea preparation Phase 2: Participants recruitment Study participants will be recruited via circulating SIBO screening questionnaires throughout the university. Individuals with mean symptomatic score (≥4) and fulfilling the inclusion criteria will be examined using a confirmatory test known as the hydrogen/methane breath test (BT). 50g glucose solubilized in 250 mL water given to participants orally. Breath samples will be taken every 15 minutes for 2 hours. After written and oral consent, 50 participants with positive BT results will be included in the study. Experimental design: SIBO-diagnosed individuals will be randomly assigned to two groups (treatment and control) with 25 participants in each group. The treatment group will take tea twice a day after meals for 2 months. Participants will be requested to record the following information daily: consumption of OLT and any side effects if experienced the control group will not receive tea or any other intervention. Phase 3: Assessment tests: GI symptoms, Hydrogen and methane breath test, 24-hour dietary intake, and body composition analysis will be done before and after the intervention. Statistical analysis: Microsoft excel will be used for data coding. Descriptive analysis will be carried out by using SPSS version 23 (SPSS for Windows version 23; SPSS Inc., Chicago, IL, USA). Independent sample t-test and Pearson chi-square test will be used to compare control and treatment groups. Paired sample t-test will be performed to measure within-group differences from the baseline. A chi-square test will be applied to develop a correlation between age, gender, and BMI with SIBO. P<0.05 was considered significant for all analysis ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05915767
Study type Interventional
Source University of Veterinary and Animal Sciences, Lahore - Pakistan
Contact
Status Completed
Phase N/A
Start date June 1, 2023
Completion date December 15, 2023

See also
  Status Clinical Trial Phase
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02251483 - Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Completed NCT00680836 - Gulf War Digestive Health Study N/A
Enrolling by invitation NCT03659175 - Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Terminated NCT04316806 - Effect of a Probiotic Formula on Reducing SIBO in IBS Patients N/A
Completed NCT05765994 - Small Intestinal Bacterial Overgrowth in Critically Ill Patients
Not yet recruiting NCT06317441 - The Safety and Efficacy of a Probiotic Intervention on SIBO and Related Gastrointestinal Symptoms N/A
Recruiting NCT05967871 - Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth Phase 1
Enrolling by invitation NCT04501380 - Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) Phase 2
Completed NCT03692299 - Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis Phase 4
Recruiting NCT04910815 - Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. N/A
Recruiting NCT04499742 - Comparative Assessment of Radioisotope Glucose and Breath Test
Enrolling by invitation NCT02458781 - Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth Phase 4
Enrolling by invitation NCT01822470 - Small Intestinal Bacterial Overgrowth: A Prospective Registry
Terminated NCT02439307 - Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial N/A
Completed NCT03216239 - SIBO & SIFO After Colectomy
Completed NCT00619970 - Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth? N/A